Medically reviewed by Drugs.com. Last updated on Jun 22, 2021.
The recommended dosage of QINLOCK is 150 mg orally once daily with or without food until disease progression or unacceptable toxicity.
Instruct patients to swallow tablets whole.
Advise patients to take QINLOCK at the same time each day.
Advise patients to take a missed dose if less than 8 hours have passed since the missed scheduled dose.
Advise patients not to take an additional dose if vomiting occurs after taking QINLOCK and to continue with their next scheduled dose.
Dosage Modifications for Adverse Reactions
The recommended dose reduction for adverse reactions is:
- QINLOCK 100 mg orally once daily.
Permanently discontinue QINLOCK in patients who are unable to tolerate 100 mg orally once daily.
The recommended dosage modifications of QINLOCK for adverse reactions are provided in Table 1.
|Adverse Reaction||Severitya||QINLOCK Dosage Modifications|
a Graded per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (NCI CTCAE v4.03).
|Palmar-Plantar Erythrodysesthesia Syndrome (PPES) [see Warnings and Precautions (5.1)]||Grade 2||
|Hypertension [see Warnings and Precautions (5.3)]||Grade 3||
||Permanently discontinue QINLOCK.|
|Left Ventricular Systolic Dysfunction [see Warnings and Precautions (5.4)]||Grade 3 or 4||Permanently discontinue QINLOCK.|
|Arthralgia or Myalgia [see Adverse Reactions (6.1)]||Grade 2||
|Other Adverse Reactions [see Adverse Reactions (6.1)]||Grade 3 or 4||
Dose Modifications for Moderate CYP3A Inducers
Avoid concomitant use of moderate CYP3A inducers during QINLOCK treatment.
If a moderate CYP3A inducer cannot be avoided, increase the QINLOCK dosing frequency from the recommended dose of 150 mg once daily to 150 mg twice daily during the co-administration period. Monitor for clinical response and tolerability. If the concomitant moderate CYP3A inducer is discontinued, resume QINLOCK dosage back to 150 mg once daily 14 days after the discontinuation of the moderate CYP3A inducer. [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].
More about Qinlock (ripretinib)
- Side effects
- Drug interactions
- During pregnancy or Breastfeeding
- Drug images
- Pricing & coupons
- En español
- Drug class: multikinase inhibitors
- FDA approval history
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.